BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · IEX Real-Time Price · USD
2.570
+0.010 (0.39%)
At close: May 3, 2024, 4:00 PM
2.580
+0.010 (0.39%)
After-hours: May 3, 2024, 5:55 PM EDT
BioXcel Therapeutics Revenue
In the year 2023, BioXcel Therapeutics had annual revenue of $1.38M with 268.00% growth. Revenue in the quarter ending December 31, 2023 was $376.00K with 57.98% year-over-year growth.
Revenue (ttm)
$1.38M
Revenue Growth
+268.00%
P/S Ratio
68.97
Revenue / Employee
$18,649
Employees
74
Market Cap
95.18M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.38M | 1.01M | 268.00% |
Dec 31, 2022 | 375.00K | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Eton Pharmaceuticals | 32.64M |
BrainsWay | 31.79M |
Aclaris Therapeutics | 31.25M |
Elutia | 24.75M |
Curis | 10.02M |
Oramed Pharmaceuticals | 1.34M |
BTAI News
- 9 days ago - BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024 - GlobeNewsWire
- 9 days ago - BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting - GlobeNewsWire
- 12 days ago - BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential - GlobeNewsWire
- 24 days ago - BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer's Dementia - GlobeNewsWire
- 5 weeks ago - BioXcel Therapeutics Announces $25 Million Registered Direct Offering - GlobeNewsWire
- 7 weeks ago - BioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine - GlobeNewsWire
- 7 weeks ago - BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023 - GlobeNewsWire
- 2 months ago - BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 - GlobeNewsWire